+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease



Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease



Circulation 133(16): 1574-1581



Current guidelines recommend statins in the primary prevention of cardiovascular disease on the basis of predicted cardiovascular risk without directly considering the expected benefits of statin therapy based on the available randomized, controlled trial evidence. We included 2134 participants representing 71.8 million American residents potentially eligible for statins in primary prevention from the National Health and Nutrition Examination Survey for the years 2005 to 2010. We compared statin eligibilities using 2 separate approaches: a 10-year risk-based approach (≥7.5% 10-year risk) and an individualized benefit approach (ie, based on predicted absolute risk reduction over 10 years [ARR10] ≥2.3% from randomized, controlled trial data). A risk-based approach led to the eligibility of 15.0 million (95% confidence interval, 12.7-17.3 million) Americans, whereas a benefit-based approach identified 24.6 million (95% confidence interval, 21.0-28.1 million). The corresponding numbers needed to treat over 10 years were 21 (range, 9-44) and 25 (range, 9-44). The benefit-based approach identified 9.5 million lower-risk (<7.5% 10-year risk) Americans not currently eligible for statin treatment who had the same or greater expected benefit from statins (≥2.3% ARR10) compared with higher-risk individuals. This lower-risk/acceptable-benefit group includes younger individuals (mean age, 55.2 versus 62.5 years; P<0.001 for benefit based versus risk based) with higher low-density lipoprotein cholesterol (140 versus133 mg/dL; P=0.01). Statin treatment in this group would be expected to prevent an additional 266 508 cardiovascular events over 10 years. An individualized statin benefit approach can identify lower-risk individuals who have equal or greater expected benefit from statins in primary prevention compared with higher-risk individuals. This approach may help develop guideline recommendations that better identify individuals who meaningfully benefit from statin therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 058102235

Download citation: RISBibTeXText

PMID: 26945047

DOI: 10.1161/CIRCULATIONAHA.115.018383


Related references

Current 10-year atherosclerotic cardiovascular disease risk threshold for statin eligibility is cost-effective for primary prevention. Evidence-Based Medicine 20(6): 230, 2016

Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey. Circulation 136(19): 1860-1862, 2017

A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention. JAMA Cardiology 3(11): 1090-1095, 2018

Statin Eligibility in Primary Prevention: From a Risk-Based Strategy to a Personalized Approach Based on the Predicted Benefit. American Journal of Cardiology 121(11): 1315-1320, 2018

Statin Therapy: Diabetes Mellitus Risk and Cardiovascular Benefit in Primary Prevention. Israel Medical Association Journal 20(8): 480-485, 2018

Population Impact & Efficiency of Benefit-Targeted Versus Risk-Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease. Journal of the American Heart Association 6(2), 2018

Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts. Bmc Cardiovascular Disorders 18(1): 97, 2018

Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA). Clinical Cardiology 40(3): 163-169, 2016

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults. American Family Physician 96(12): 805-806, 2018

Statin therapy for primary prevention of cardiovascular disease. JAMA 310(22): 2451-2452, 2013

Statin in the primary and secondary prevention of cardiovascular disease. Nihon Rinsho. Japanese Journal of Clinical Medicine 74 Suppl 4 Pt 1: 556-561, 2016

Statin for the primary prevention of cardiovascular disease in patients with diabetes mellitus. Diabetes and Metabolism Journal 38(1): 32-34, 2014

Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Canadian Family Physician Medecin de Famille Canadien 63(11): E495-E503, 2018

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement. American Family Physician 95(2): Online-Online, 2017

Statin for primary prevention of atherosclerotic cardiovascular disease in young adults: Are we there yet?. Trends in Cardiovascular Medicine 2019, 2019